[4] [5] Appropriate clinical management for patients with comorbid metabolic conditions and problematic alcohol use should include: Comprehensive assessment of alcohol consumption patterns using validated screening tools (AUDIT, AUDIT-C) Referral to addiction medicine specialists or behavioral health providers for evidence-based AUD treatment, especially with red flags such as history of severe withdrawal, seizures, delirium tremens, pregnancy, severe liver disease, or suicidality Consideration of FDA-approved pharmacotherapies for alcohol use disorder (naltrexone, acamprosate, disulfiram) with attention to their specific contraindications [9] [11] If GLP-1 therapy is indicated for diabetes or obesity, close monitoring for changes in alcohol consumption and related behaviors Patient education emphasizing that any effects on alcohol cravings are not established therapeutic benefits Regular follow-up to assess medication adherence, adverse effects, and overall treatment response Patients should never discontinue evidence-based treatments for alcohol use disorder in favor of unproven approaches
Retatrutide $99.99 $125.99Price range: $99.99 through $125.99 Retatrutide Triple Agonist Peptide for Metabolic Research
Therapeutic indications for Wegovy Wegovy is indicated as an adjunct to a hypocaloric diet and increased physical activity for chronic weight management in : Patients with obesity (BMI 30 kg/m) Overweight patients (BMI 27 kg/m) with at least one associated risk factor (hypertension, dyslipidemia, type 2 diabetes, etc.)
North Carolina has not enacted a state mandate requiring commercial insurers to cover GLP-1 medications for obesity as of January 2025
We confirm your coverage and connect you with an accepting provider
Brand:Alpha Labs
